John Sinden
CEO, Glialign

About me


Glialign was established in 2018 to take forward the work of UCL academics in engineering live neural tissue.

Its current project has been funded by the UCL Technology Fund, UK Innovation and Science: Seed Fund (UKI2S) and Innovate UK.

Founders James Phillips and John Sinden are currently optimising a method for producing a living nerve growth guide designated “EngNT”, which is intended as an ‘off-the-shelf’ nerve replacement – primarily for peripheral nerve repair. This represents an innovative engineering solution to an unmet clinical need.

Matchmaking Information

Processing. Please wait.